First Solar, Inc. (FSLR) stock is testing nine-year resistance on Thursday, at the cusp of a major breakout that could generate superior returns in coming years. The stock reversed at this barrier in late August and fell 20 points after the company announced an 8.6 million secondary share offering, yielding a bounce just above the 200-day exponential moving average (EMA) in the low $60s. It turned higher at the end of September and has now returned to this critical level.

Key Takeaways

  • First Solar stock has been stuck in a basing pattern since 2014.
  • The company should benefit from aggressive climate change policy.
  • The stock has rallied to resistance for the fourth time and could break out.
  • An uptrend may generate superior returns in coming years.

The solar cell manufacturer and power plant designer should thrive and prosper in this decade, with worldwide political sentiment transitioning out of fossil fuel and into alternative energy sources. The Arizona-based company will also benefit from a 2020 California law mandating solar panels on all new single- and multi-family constructions. A Democratic administration would likely augment these trends, lifting the stock to price levels not seen since 2011.

Wall Street consensus has slowly improved in 2020, with a “Moderate Buy” rating on First Solar shares based upon six “Buy,” four “Hold,” and two “Sell” recommendations. Price targets currently range from a low of $38 to a Street-high $95, while the stock is set to open Thursday’s session about $9 above the median $72 target. This placement may support an initial breakout, but further upgrades will be needed to establish a long-term uptrend.

There are two types of secondary offerings. A non-dilutive secondary offering is a sale of securities in which one or more major stockholders in a company sell all or a large


The normalizing of coronavirus is happening even as the crisis grips the nation. The change arrives in big and small ways, some of them loudly, some not.

Connecticut opens up restaurants to 75 percent capacity on Thursday. That’s a high-profile normalizer.

President

Report shows insurance coverage of biomarker testing has not kept up with innovation

PR Newswire

WASHINGTON, Sept. 29, 2020

LUNGevity Foundation and American Cancer Society Cancer Action Network report indicates some improvement but substantial gaps still exist for many patients

WASHINGTON, Sept. 29, 2020 /PRNewswire/ — LUNGevity Foundation, the nation’s premier lung cancer-focused nonprofit organization, in partnership with the American Cancer Society Cancer Action Network (ACS CAN), issued a report today analyzing private payer health insurance coverage of biomarker testing for non-small cell lung, colorectal, breast, and prostate cancers. The study serves as an update to a similar review of health care coverage issued by both organizations in 2018.

LUNGevity Foundation logo (PRNewsfoto/LUNGevity Foundation)
LUNGevity Foundation logo (PRNewsfoto/LUNGevity Foundation)

Since 2015, LUNGevity has been working to ensure that all advanced-stage non-small cell lung cancer patients have access to comprehensive biomarker testing at diagnosis, progression, and recurrence, and have the results before making treatment decisions. LUNGevity defines comprehensive biomarker testing as a multiplex panel (also referred to as a multi-gene panel in the report, such as a Next Generation Sequencing panel) to detect multiple mutations including, at a minimum, EGFR, ALK, ROS-1, BRAF, NTRK, RET, MET, HER-2, KRAS, and an immunohistochemistry test to measure levels of the protein PDL1.

Limitations in health care insurance coverage often affect access to these vital advances, which leads to disparities in treatment. The report found that private payer health care coverage is more prominent for single-gene tests. However, health insurance companies are still slow to cover targeted multiplex panels and other forms of testing, such as minimally invasive liquid biopsies, also known as blood-based biomarker testing.

“LUNGevity is proud to partner with ACS CAN on this study as part of our ongoing commitment to improving the lives of cancer patients,” explained LUNGevity Senior Director of Public Policy Initiatives Kristen